SEC Form 4 · accession 0001209191-17-039989
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Jun 12, 2017
Accepted (ET)
Jun 14, 2017 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2017 | M | 8,300 | $2.55 | A | 177,519 | D | |
| Common StockF1 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.55 | Jun 12, 2017 | M | 8,300 | D | — | Jul 20, 2020 | Common Stock | 8,300 | 11,321 | D |
Explanation of responses
- F1These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
- F2The Option is fully vested as of January 1, 2014.